Singapore, Feb. 20 -- Expecto Health Science, a Singapore-headquartered, Asia-focused clinical research organization (CRO), and Southern Star Research (SSR), a leading Australia-based CRO, announced a strategic investment-driven partnership.

The investment marks a significant milestone in Expecto Health Science's long-term growth strategy, accelerating its ability to deliver seamless, end-to-end clinical trial execution across the Asia-Pacific region.

This alliance establishes a powerful cross-regional collaboration, enabling sponsors to transition efficiently from early-phase studies in Australia and New Zealand to late-phase clinical development programs across key Asian markets.

"This strategic investment reinforces our vision of bu...